Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-25T06:53:51.421Z Has data issue: false hasContentIssue false

Tacrine for Alzheimer's disease: a complex decision

Published online by Cambridge University Press:  13 June 2014

Kenneth L Davis*
Affiliation:
Mount Sinai School of Medicine, One Gustav L Levy Place, New York, NY 10029-6574, USA
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Copyright
Copyright © Cambridge University Press 1995

References

1.Leber, P. Guidelines for the clinical evaluation of antidementia drugs, first draft. Rockville, MD: US Food and Drug Administration, 1990.Google Scholar
2.CPMP Working Party on Efficacy of Medicinal Products. Antidementia medicinal products. Commission of the European Communities: Brussels, 1992.Google Scholar
3.Davis, KL, Thal, LJ, Gamzu, ER, et al.A double-blind, placebo-controlled multicenter trial of tacrine in Alzheimer's disease. New Engl J Med 1992; 327:1253–9.CrossRefGoogle Scholar
4.Farlow, M, Gracon, SI, Hershey, LA, et al.A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268:2523-9.CrossRefGoogle ScholarPubMed
5.Watkins, PB, Zimmerman, HJ, Knapp, MJ, et al.Hepatoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271 (13): 1023–4.CrossRefGoogle Scholar
6.Moore, MJ, Clipp, EC. Alzheimer's disease and caregiver time. Lancet 1994; 343:239–40.CrossRefGoogle ScholarPubMed
7.Summers, WK, Majovski, LV, Marsh, GM, et al.Oral tetrahydroamionoacridine in long-term treatment of senile dementia, Alzheimer's disease. New Engl J Med 1986; 315: 1241–5.CrossRefGoogle Scholar